SALUGGIA, Italy, HILDEN,
Germany, and GERMANTOWN, Maryland, January 8, 2018 /PRNewswire/ --
- QIAGEN's QuantiFERON-TB
customers to gain access
to fully automated
workflow solution
- DiaSorin to add novel content
to already broad LIAISON
menu, over 7,000
systems installed
- QIAGEN announces milestone of
over 40 million
QuantiFERON-TB tests since
launch
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Stock Exchange: QIA)
and DiaSorin (FTSE Italy Mid Cap: DIA) announced today a
groundbreaking partnership that plans to add QIAGEN's
QuantiFERON-TB diagnostic test to the menu of DiaSorin's LIAISON
family of fully automated analyzers.
This addition will enable customers of both companies to process
QuantiFERON-TB Gold Plus (QFT-Plus), the fourth-generation modern
gold standard for latent tuberculosis (TB) detection, on LIAISON
family platforms. Laboratories using QFT-Plus to safeguard at-risk
patients by screening for latent TB infection will have access to a
fully automated, flexible workflow on LIAISON family analyzers in
addition to the currently available workflow solutions. More than
7,000 LIAISON systems have already placed worldwide, primarily in
hospital laboratories.
QFT-Plus marks the first assay from QIAGEN's QuantiFERON
portfolio that is planned to be adapted for use on the LIAISON
family systems. Additional assays based on QuantiFERON technology,
which offers a unique, efficient way to detect asymptomatic
infections and other risks that cannot be discovered with standard
diagnostic technologies, are under consideration.
QuantiFERON assays such as QFT-Plus are based on two components:
(1) QuantiFERON Blood Collection Tubes, which contain key
components of the test reaction that is uniquely performed in tube
after blood collection; and (2) the QuantiFERON test read-out
components, which are used to measure the release of interferon
gamma after in-tube incubation. QFT-Plus currently runs in
laboratories on standard detection equipment.
Click here for the full press
release: https://corporate.qiagen.com/newsroom/press-releases/2017/20180108_DiaSorin_LIAISON_QFT?sc_lang=en
For additional information, please contact
For DiaSorin
Riccardo Fava
Investor Relations & Corporate Communication Senior
Director
Tel: +39.0161.487988
riccardo.fava@diasorin.it
Ines Di Terlizzi
Investor Relator
Tel: +39.0161.487567
ines.diterlizzi@diasorin.it
For QIAGEN
Investor Relations
John Gilardi
Tel: +49 2103 29 11711
e-mail: ir@QIAGEN.com
Public Relations
Thomas Theuringer
Tel: +49 2103 29 11826
e.mail: pr@QIAGEN.com
SOURCE Qiagen N.V.